Notably, silent information regulator of transcription 1 (SIRT1), a key mediator of energy metabolism among multiple signalling pathways and a potential therapeutic target for the treatment of NAFLD [38, 39], appears to be a common direct target of miR-132, miR-146b, and miR-34a. This evidence concerns the gene SIRT1 and metabolic dysfunction-associated steatotic liver disease.